John J Cush

Summary

Affiliation: Baylor University Medical Center
Country: USA

Publications

  1. ncbi request reprint Early rheumatoid arthritis -- is there a window of opportunity?
    John J Cush
    Department of Clinical Rheumatology, Baylor Research Institute, Dallas, Texas 75231, USA
    J Rheumatol Suppl 80:1-7. 2007
  2. doi request reprint Refining drug safety in rheumatology
    John J Cush
    Baylor Research Institute, Baylor University Medical Center, Dallas, TX, USA
    Rheum Dis Clin North Am 38:xi-xiv. 2012
  3. doi request reprint Malignancy risks with biologic therapies
    John J Cush
    Baylor Research Institute, Dallas, TX 75229, USA
    Rheum Dis Clin North Am 38:761-70. 2012
  4. doi request reprint Nonserious infections: should there be cause for serious concerns?
    Kathryn H Dao
    Baylor Research Institute, Dallas, TX 75229, USA
    Rheum Dis Clin North Am 38:707-25. 2012
  5. ncbi request reprint Acute polyarthritis
    Kathryn Dao
    Rheumatology and Clinical Immunology Division, Presbyterian Hospital of Dallas, Dallas, TX 75231, USA
    Best Pract Res Clin Rheumatol 20:653-72. 2006
  6. ncbi request reprint Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence
    Stanley B Cohen
    The University of Texas Southwestern Medical Center, Office of Continuing Education, 5323 Harry Hines Blvd, Dallas, TX 75390 9059, USA
    J Rheumatol Suppl 81:4-30; quiz 31-4. 2008
  7. ncbi request reprint Remodeling a rheumatology practice to facilitate early referral
    John J Cush
    Department of Rheumatology and Clinical Immunology, Presbyterian Hospital of Dallas, 8200 Walnut Hill Lane, Dallas, TX 75231 4496, USA
    Rheum Dis Clin North Am 31:591-604. 2005
  8. ncbi request reprint Autoinflammatory syndromes
    John J Cush
    Baylor Research Institute, Rheumatology Research, 9900 North Central Expressway, Suite 550, Dallas, TX 75231, USA
    Dermatol Clin 31:471-80. 2013
  9. ncbi request reprint Safety overview of new disease-modifying antirheumatic drugs
    John J Cush
    Presbyterian Hospital of Dallas, 8200 Walnut Hill Lane, Dallas, TX 75231, USA
    Rheum Dis Clin North Am 30:237-55, v. 2004
  10. ncbi request reprint Early arthritis clinics: if you build it will they come?
    John J Cush
    J Rheumatol 32:203-7. 2005

Detail Information

Publications13

  1. ncbi request reprint Early rheumatoid arthritis -- is there a window of opportunity?
    John J Cush
    Department of Clinical Rheumatology, Baylor Research Institute, Dallas, Texas 75231, USA
    J Rheumatol Suppl 80:1-7. 2007
    ....
  2. doi request reprint Refining drug safety in rheumatology
    John J Cush
    Baylor Research Institute, Baylor University Medical Center, Dallas, TX, USA
    Rheum Dis Clin North Am 38:xi-xiv. 2012
    ..The use of both conventional and novel therapies mandates an understanding of the mechanisms of action, unique toxicities, screening and monitoring measures, and rules for drug avoidance...
  3. doi request reprint Malignancy risks with biologic therapies
    John J Cush
    Baylor Research Institute, Dallas, TX 75229, USA
    Rheum Dis Clin North Am 38:761-70. 2012
    ..This article addresses the growing data on the short- and long-term cancer risks associated with biologic use in RA...
  4. doi request reprint Nonserious infections: should there be cause for serious concerns?
    Kathryn H Dao
    Baylor Research Institute, Dallas, TX 75229, USA
    Rheum Dis Clin North Am 38:707-25. 2012
    ..A systemic review of large, randomized controlled trials was conducted to identify incidence, types, and outcomes of NSIE associated with the most commonly prescribed TNFi: adalimumab, etanercept, and infliximab...
  5. ncbi request reprint Acute polyarthritis
    Kathryn Dao
    Rheumatology and Clinical Immunology Division, Presbyterian Hospital of Dallas, Dallas, TX 75231, USA
    Best Pract Res Clin Rheumatol 20:653-72. 2006
    ..This chapter reviews the evidence to help clinicians identify and manage patients who present with acute polyarticular inflammation...
  6. ncbi request reprint Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence
    Stanley B Cohen
    The University of Texas Southwestern Medical Center, Office of Continuing Education, 5323 Harry Hines Blvd, Dallas, TX 75390 9059, USA
    J Rheumatol Suppl 81:4-30; quiz 31-4. 2008
    ..In this program, distinguished rheumatologists weigh the evolving body of clinical evidence to draw sound conclusions and resolve key issues in managing inadequate response to treatment and in achieving optimal outcomes in RA...
  7. ncbi request reprint Remodeling a rheumatology practice to facilitate early referral
    John J Cush
    Department of Rheumatology and Clinical Immunology, Presbyterian Hospital of Dallas, 8200 Walnut Hill Lane, Dallas, TX 75231 4496, USA
    Rheum Dis Clin North Am 31:591-604. 2005
    ..The slow growth of early arthritis clinics is summarized in a survey that characterizes 23 early arthritis programs in North America. Also, several screening tools and models to capture these early-onset arthritis patients are presented...
  8. ncbi request reprint Autoinflammatory syndromes
    John J Cush
    Baylor Research Institute, Rheumatology Research, 9900 North Central Expressway, Suite 550, Dallas, TX 75231, USA
    Dermatol Clin 31:471-80. 2013
    ....
  9. ncbi request reprint Safety overview of new disease-modifying antirheumatic drugs
    John J Cush
    Presbyterian Hospital of Dallas, 8200 Walnut Hill Lane, Dallas, TX 75231, USA
    Rheum Dis Clin North Am 30:237-55, v. 2004
    ..This article discusses the safety issues arising from clinical trial and postmarketing experience with several new and commonly used agents, with specific emphasis on adalimumab, etanercept, infliximab, anakinra, and leflunomide...
  10. ncbi request reprint Early arthritis clinics: if you build it will they come?
    John J Cush
    J Rheumatol 32:203-7. 2005
  11. ncbi request reprint The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis
    Arthur Kavanaugh
    J Rheumatol 31:1881-4. 2004
  12. ncbi request reprint The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis
    Karen E Hansen
    Division of Rheumatology, University of Wisconsin, Madison, Wisconsin, USA
    J Rheumatol 31:1098-102. 2004
    ..To describe the degree of clinical benefit in patients with rheumatoid arthritis (RA) who receive infliximab therapy after lack of efficacy with etanercept...
  13. ncbi request reprint Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial
    Joel M Kremer
    The Center for Rheumatology, LLP, 1367 Washington Avenue, Suite 101, Albany, NY 12206, USA
    Ann Intern Med 137:726-33. 2002
    ..Disease-modifying antirheumatic drugs may confer greater benefits when combined with the antimetabolite methotrexate...